http://orcid.org/0000-0001-6220-2220
References
- Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Canton R, Torres A, Dimakou K, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
- Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends. PLoS One. 2013;8(8):e71109.
- Hill AT, Bilton D, Brown J. BTS quality standards for clinically significant bronchiectasis in adults. Br Thorac Soc Rep. 2012;4:1–16.
- Hill AT, Routh C, Welham S. National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? Thorax. 2014;69(3):292–4.
- Aliberti S, Hill AT, Mantero M, Battaglia S, Centanni S, Lo Cicero S, Lacedonia D, Saetta M, Chalmers JD, Blasi F, et al. Quality standards for the management of bronchiectasis in Italy: a national audit. Eur Respir J. 2016;48(1):244–8.
- Blanchette CM, Noone JM, Stone G, Zacherle E, Patel RP, Howden R, Mapel D. Healthcare cost and utilization before and after diagnosis of Pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the U.S. Med Sci. 2017;5(4):E20. doi:10.3390/medsci5040020.
- Arauko D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51(2):1701953.
- Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12:1602–11.
- Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014;44:382–93. doi:10.1183/09031936.00018414.
- Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med. 2011;105(6):946–9. doi:10.1016/j.rmed.2011.01.009.
- Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660–7. doi:10.1016/S0140-6736(12)60953-2.
- Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–9. doi:10.1001/jama.2013.1937.
- Anning L, McNeill M, Rose A, Mortimer H, Withers N. The use of home intravenous antibiotics in adult non-CF bronchiectasis. Eur Respir J. 2015;46:PA2626.
- Farrel K, Wicks MN, Martin JC. Chronic disease self-management improved with enhanced self-efficacy. Clin Nurs Res. 2004;13(4):289–308. doi:10.1177/1054773804267878.
- Haworth CS, Johnson C, Aliberi S, Goeminne PC, Ringhausen F, Boersma W, De Soyza A, Murris M, Polverino E, Vendrell M, et al. Management of bronchiectasis in Europe: data from the European bronchiectasis registry (EMBARC). Eur Respir J. 2016;48:OA273. doi:10.1183/13993003.